<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695188</url>
  </required_header>
  <id_info>
    <org_study_id>PROMTX2007_01</org_study_id>
    <secondary_id>EudraCT: 2007-006288-56</secondary_id>
    <nct_id>NCT00695188</nct_id>
  </id_info>
  <brief_title>Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis A Multicenter, Randomized, Double-blind, Controlled Phase IV Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Boltzmann Institut fuer Rheumatologie, Balneologie und Rehabilitation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Boltzmann Institut fuer Rheumatologie, Balneologie und Rehabilitation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine whether erythrocyte polyglutamate levels are associated
      with objective clinical response in patients with rheumatoid arthritis after oral
      administration of low-dose methotrexate.The secondary aim of this study is to compare the
      efficacy and safety of standard dose methotrexate versus a higher starting dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The folate antagonist methotrexate (MTX) is currently one of the most widely used drugs for
      the treatment of rheumatoid arthritis (RA).Although MTX is very effective and well tolerated,
      the major drawback is the large interpatient variability in the clinical response.MTX is
      intracellularly converted by folylpolyglutamate synthetase (FPGS) to methotrexate
      polyglutamates (MTXPGs), which enhance the intracellular retention of MTX. Furthermore, the
      Î³-linked sequential addition of glutamic acid residues inhibits finals steps in the de novo
      purine and pyrimidine biosynthesis, resulting in anti-proliferative and anti-inflammatory
      effects.76 adult, MTX-naive patients who fulfill the American College of Rheumatology
      criteria (ACR) for RA with a Disease Activity Score in 28 joints (DAS-28) &gt; 3.2 are enrolled
      at two sites in Vienna (Austria).Clinical status is assessed by the number of joint counts
      and the Health Assessment Questionnaire (HAQ).Patients are randomly assigned to receive
      either a standard dose or a higher starting dose of 25 mg orally. In week 5, a subcutaneous
      dose of 25 mg is administered to each patient to get a reference level (bioavailability of
      100%).The patients participate for 16 weeks, in which blood samples are collected at weeks 1,
      2, 5, 6, 10 and 11 to perform pharmacokinetic analyses and metabolite measurements.The
      determination of erythrocyte MTXPG-levels is performed by using a HPLC technique.The primary
      outcome is the objective clinical response (measured in a rheumatic score, DAS-28), secondary
      outcome parameters are quality of life and routine laboratory parameters used in
      rheumatology. This clinical outcome will be correlated with MTX pharmacokinetics in blood,
      MTXPG kinetics in erythrocytes, and their impact on the folate pathway.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DAS-28 (Disease Activity Score in 28 Joints)</measure>
    <time_frame>16 weeks</time_frame>
    <description>DAS stands for &quot;Disease Activity Score&quot; and is a measure of the activity of rheumatoid arthritis. In Europe the DAS is the recognized standard in research and clinical practice.
The following parameters are included in the calculation:
Number of joints tender to the touch (TEN)
Number of swollen joints (SW)
Erythrocyte sedimentation rate (ESR)
Patient assessment of disease activity (VAS; mm)
The DAS-28 is evaluated using a scale:
0 - 3.2: low disease activity 3.2 - 5.1: moderate disease activity &gt; 5.1: severe disease activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAQ (Health Assessment Questionnaire)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Standard dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Escalating dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>oral administration Escalating dose (15, 20, 25 mg)</description>
    <arm_group_label>Standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>25 mg oral administration</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MTX-naive

          -  Age &gt; 18 years

          -  DAS-28 &gt; 3.2

          -  American College of Rheumatology-criteria for RA

          -  Chest-X-ray

          -  Informed consent

          -  Prednisolon &lt; 10 mg a day

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Renal and hepatic impairment

          -  Malignant diseases (last 5 years)

          -  Contraindications

          -  Human Immunodeficiency Virus (HIV), Hepatitis B and C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Broell, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Boltzmann-Institut fuer Rheumatologie und Balneologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser-Franz-Josef-Spital</name>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Wien Oberlaa</name>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <results_first_submitted>December 20, 2010</results_first_submitted>
  <results_first_submitted_qc>January 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 15, 2011</results_first_posted>
  <last_update_submitted>February 15, 2011</last_update_submitted>
  <last_update_submitted_qc>February 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prim. Univ.-Prof. Dr. Hans Broell</name_title>
    <organization>Ludwig-Boltzmann Institut fuer Rheumatologie und Balneologie</organization>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>MTX polyglutamates</keyword>
  <keyword>clinical outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were included at the outpatient unit of the Kaiser-Franz-Josef-Hospital, Department for Rheumatology, if they fulfilled the inclusion criteria</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Dose</title>
          <description>Escalating dose (Start with 15 mg MTX/week, escalating dose until 25 mg/week, administered orally)</description>
        </group>
        <group group_id="P2">
          <title>High Dose</title>
          <description>Start with 25 mg MTX per week, administered orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Dose</title>
          <description>Escalating dose (Start with 15 mg MTX/week, escalating dose until 25 mg/week, administered orally)</description>
        </group>
        <group group_id="B2">
          <title>High Dose</title>
          <description>Start with 25 mg MTX per week, administered orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="15"/>
                    <measurement group_id="B2" value="62" spread="7"/>
                    <measurement group_id="B3" value="56" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>DAS-28 (Disease Activity Score in 28 Joints)</title>
        <description>DAS stands for &quot;Disease Activity Score&quot; and is a measure of the activity of rheumatoid arthritis. In Europe the DAS is the recognized standard in research and clinical practice.
The following parameters are included in the calculation:
Number of joints tender to the touch (TEN)
Number of swollen joints (SW)
Erythrocyte sedimentation rate (ESR)
Patient assessment of disease activity (VAS; mm)
The DAS-28 is evaluated using a scale:
0 - 3.2: low disease activity 3.2 - 5.1: moderate disease activity &gt; 5.1: severe disease activity</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose</title>
            <description>Escalating dose (Start with 15 mg MTX/week, escalating dose until 25 mg/week, administered orally)</description>
          </group>
          <group group_id="O2">
            <title>High Dose</title>
            <description>Start with 25 mg MTX per week, administered orally</description>
          </group>
        </group_list>
        <measure>
          <title>DAS-28 (Disease Activity Score in 28 Joints)</title>
          <description>DAS stands for &quot;Disease Activity Score&quot; and is a measure of the activity of rheumatoid arthritis. In Europe the DAS is the recognized standard in research and clinical practice.
The following parameters are included in the calculation:
Number of joints tender to the touch (TEN)
Number of swollen joints (SW)
Erythrocyte sedimentation rate (ESR)
Patient assessment of disease activity (VAS; mm)
The DAS-28 is evaluated using a scale:
0 - 3.2: low disease activity 3.2 - 5.1: moderate disease activity &gt; 5.1: severe disease activity</description>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="0.93"/>
                    <measurement group_id="O2" value="2.66" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HAQ (Health Assessment Questionnaire)</title>
        <time_frame>16 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Dose</title>
          <description>Escalating dose (Start with 15 mg MTX/week, escalating dose until 25 mg/week, administered orally)</description>
        </group>
        <group group_id="E2">
          <title>High Dose</title>
          <description>Start with 25 mg MTX per week, administered orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea after the intake of methotrexate</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eva-Luise Hobl</name_or_title>
      <organization>Department of Clinical Pharmacology, Medical University of Vienna</organization>
      <phone>+43 1 40400 2981</phone>
      <email>eva-luise.hobl@meduniwien.ac.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

